Free Trial
NASDAQ:NUVL

Nuvalent Q3 2023 Earnings Report

Nuvalent logo
$83.40 -2.29 (-2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$83.38 -0.02 (-0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.58
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Nuvalent Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvalent Announcement Details

Quarter
Q3 2023
Time
Before Market Opens
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Nuvalent's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nuvalent Earnings Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Nuvalent Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvalent? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvalent and other key companies, straight to your email.

About Nuvalent

Nuvalent (NASDAQ:NUVL) is a clinical‐stage precision oncology company focused on the discovery and development of small molecule inhibitors for genetically defined cancers. Founded in 2019 and headquartered in Cambridge, Massachusetts, Nuvalent leverages a structure‐based drug design platform to address oncogenic targets that have proven difficult to inhibit with traditional therapies.

The company’s lead program targets the KRAS G12D mutation, one of the most prevalent oncogenic drivers in pancreatic, colorectal and other solid tumors, and is currently in early‐stage clinical evaluation. In parallel, Nuvalent is advancing additional candidate molecules against key drivers such as EGFR exon 20 insertion mutations and FGFR fusions, with the goal of offering new treatment options for patients with high unmet need.

Nuvalent’s discovery platform integrates covalent chemistry, high‐resolution structural analysis and proprietary screening methodologies to rapidly identify and optimize potent, selective compounds. Its research facility in Cambridge supports a multidisciplinary team of medicinal chemists, structural biologists and translational scientists working in close collaboration with clinical development experts.

James Sapirstein, co‐founder and Chief Executive Officer, leads the organization alongside a leadership team drawn from top biopharmaceutical companies and academic institutions. Under their stewardship, Nuvalent has established strategic collaborations and plans to initiate global clinical trials across North America and Europe, aiming to bring first‐in‐class precision medicines to cancer patients worldwide.

View Nuvalent Profile

More Earnings Resources from MarketBeat